Jennifer Schmitke
Directeur des opérations chez IMV INC.
Postes actifs de Jennifer Schmitke
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IMV INC. | Directeur des opérations | - | - |
Historique de carrière de Jennifer Schmitke
Anciens postes connus de Jennifer Schmitke
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| EPIZYME, INC. | Corporate Officer/Principal | - | 01/04/2022 |
| BIOGEN INC. | Directeur/Membre du Conseil | - | - |
| OMEGA THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - | - |
Formation de Jennifer Schmitke
| Queen's University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
| Canada | 3 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 6 |
| Consumer Services | 2 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| OMEGA THERAPEUTICS, INC. | Health Technology |
| IMV INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Jennifer Schmitke
- Expérience
